Ciclesonide
Appearance
![]() | |
![]() | |
Clinical data | |
---|---|
Trade names | Omnaris, others |
Other names | (11β, 16α)-16, 17-[[(R)-cyclohexylmethylene]bis(oxy)]-11-hydroxy-21- (2-methyl-1-oxopropoxy)- pregna-1, 4-diene-3, 20-dione |
AHFS/Drugs.com | Monograph |
MedlinePlus | a607008 |
Pregnancy category |
|
Routes of administration | Nasal inhalation |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.210.908 |
Chemical and physical data | |
Formula | C32H44O7 |
Molar mass | 540.697 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
Ciclesonide, sold under the brand name Omnaris among others, is a glucocorticoid used to treat asthma and allergic rhinitis.
Side effects of the medication include headache, nosebleeds, and inflammation of the nose and throat linings.[6]
It was patented in 1990 and approved for medical use in 2005.[7] The drug was approved for adults and children 12 and over by the US Food and Drug Administration in October 2006.[8] It is on the World Health Organization's List of Essential Medicines.[9]
Society and culture
Brand names
It is marketed under the brand names Alvesco for asthma and Omnaris, Omniair, Zetonna, and Alvesco for hay fever in the US and Canada.
References
- ^ "Omnaris- ciclesonide spray". DailyMed. 8 November 2022. Retrieved 29 June 2024.
- ^ "Alvesco- ciclesonide aerosol, metered". DailyMed. 16 February 2023. Retrieved 29 June 2024.
- ^ "Zetonna- ciclesonide aerosol, metered". DailyMed. 16 February 2023. Retrieved 29 June 2024.
- ^ "Aservo Equihaler- ciclesonide spray, metered". DailyMed. 16 September 2021. Retrieved 29 June 2024.
- ^ "Aservo Equihaler EPAR". European Medicines Agency. 28 February 2020. Retrieved 29 June 2024.
- ^ Mutch E, Nave R, McCracken N, Zech K, Williams FM (May 2007). "The role of esterases in the metabolism of ciclesonide to desisobutyryl-ciclesonide in human tissue". Biochemical Pharmacology. 73 (10): 1657–1664. doi:10.1016/j.bcp.2007.01.031. PMID 17331475.
- ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 488. ISBN 9783527607495.
- ^ "FDA News Release. FDA Approves New Treatment for Allergies". Food and Drug Administration. 23 October 2006. Retrieved 30 July 2009.
- ^ World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
Further reading
- Rossi S, ed. (2006). Australian Medicines Handbook. Adelaide: Australian Medicines Handbook. ISBN 0-9757919-2-3.